Open Access

Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood

  • L Zachau1,
  • C Zeckey2,
  • J Schlue3,
  • J Sander1,
  • C Meyer-Heithuis4,
  • M Winkler1,
  • J Klempnauer1 and
  • H Schrem1Email author
World Journal of Surgical Oncology201210:98

https://doi.org/10.1186/1477-7819-10-98

Received: 3 February 2012

Accepted: 30 May 2012

Published: 30 May 2012

Abstract

Background

Cases with subcutaneous metastasis of differentiated hepatocellular carcinoma to the abdominal wall without prior seeding as a consequence of local interventions with a negative or normal alpha-fetoprotein level in the serum are extremely rare.

Case report

This is the first report of a case with AFP-negative, differentiated hepatocellular carcinoma metastasis to the abdominal wall within a pre-existing subcutaneous lipoma since childhood after antiandrogen therapy with leuprorelin and buserelin acetate for prostate cancer without seeding.

Methods

Clinical features including histology, immunohistochemistry, clinical course and surgical approach are presented.

Results

Histological examination revealed a hepatocellular carcinoma with a trabecular and pseudoglandular growth pattern with moderately atypical hepatocytes with multifocal bile formation within a lipoma. The postoperative course of abdominal wall reconstruction with a monocryl-prolene mesh and a local flap after potentially curative resection was uncomplicated.

Discussion and conclusion

It may be that previous antiandrogen treatment for prostate carcinoma contributed to the fact that our patient developed alpha-fetoprotein-negative and androgen receptor-negative subcutaneous abdominal wall metastasis within a pre-existing lipoma since childhood.

Keywords

Hepatocellular carcinomaCutaneous metastasisAntiandrogen therapy

Background

Hepatocellular carcinoma (HCC) remains one of the most common malignant diseases and the incidence is increasing worldwide [15]. Today, a multidisciplinary approach including surgical, chemotherapeutic and interventional therapeutic modalities is regarded as a prerequisite to enable optimal results. Distant metastases are common, the most frequent sites include the lungs, bones, lymph nodes and adrenal glands but extrahepatic metastasis to the abdominal wall is comparatively very rare [610].

Cases with subcutaneous differentiated metastasis of hepatocellular carcinoma with a negative or normal alpha-fetoprotein (AFP) level in the serum are extremely rare (see Table 1) [1136].
Table 1

Non-iatrogenic skin metastasis from hepatocellular carcinoma described in the literature the last 10 years.

Reference

N

Sex

Age

Localisation

Seeding

AFP ng/ml

Appearance

Hepatitis

Jegou et al. (2004) [11]

1

M

55

left frontal

no

n.a.

painless nodule

n.a.

De Agustin et al. (2007) [12]

1

F

65

face

no

n.a.

n.a.

n.a.

Hsieh et al. (2007) [13]

1

M

46

left skull

no

71 ng/ml

soft mass

B

Royer et al. (2008) [14]

1

M

74

nose

no

n.a.

pearly purple nodule

n.a.

Magana and Gomez et al. (2009) [15]

1

M

41

right cheek

no

n.a

red papule

C

Lazaro et al. (2009) [16]

1

M

61

nasal lesion

no

n.a.

excoriated palpule

n.a.

Fukushima et al. (2010) [17]

1

M

58

left skull

no

n.a

n.a

n.a

Lee et al. (2010) [18]

1

M

49

tip of nose

no

n.a.

dark spot

C

Isa et al. (2011) [19]

1

M

81

left nasal alae

no

normal

multilobulated mass

negative

Ackerman et al. (2001) [20]

1

M

52

left scapula

no

10000 ng/ml

hemangio-sarcoma

B,C

Braune et al. (2001) [21]

1

M

76

right chest

yes

n.a.

subcutaneous tumor

n.a.

Al-Mashat FM (2004) [22]

1

M

60

chest wall

n.a.

n.a.

n.a.

n.a.

Amador et al. (2007) [23]

1

M

80

shoulder

no

n.a.

abscess-like

B

Terada et al. (2010) [24]

1

M

86

right chest

no

n.a

cutaneous mass

C

Suzuki et al. (2003) [25]

1

M

66

abdomen

n.a.

n.a.

subcutaneous nodule

C

Lee et al. (2004) [26]

1

M

68

right upper abdomen

yes

normal

red nodule

B

Hyun et al. (2006) [27]

1

M

56

left abdomen

no

308 ng/ml

n.a.

B

Nggada et al. (2006) [28]

1

M

53

chest, back abdomen,

no

negative

nodules

B

Martinez Ramos et al. (2007) [29]

1

W

70

subxyphoid region

yes

324000 ng/ml

violaceous cutaneous mass

C

Rowe et al. (2007) [30]

1

W

72

abdominal wall

yes

n.a.

nodule

no

Özdil et al. (2009) [31]

1

M

76

right abdomen

yes

1860 ng/ml

subcutaneous tumor

B

Chen et al. (2011) [32]

1

F

69

abdominal wall

yes

275-1217 ng/ml

n.a

C

Fang et al. (2001) [33]

1

M

49

back, hands, feet

no

n.a.

reddish-blue papules

n.a.

Kanitakis et al. (2003) [34]

1

F

50

right arm

no

increased

n.a.

n.a.

Nagaoka et al. (2004) [35]

1

F

77

right waist

yes

8 ng/ml

reddish papules

n.a.

Masannat et al. (2007) [36]

1

M

63

left calf

no

5 ng/ml

like soft-tissue sarcoma

n.a.

(AFP, alpha-fetoprotein; n.a.: not applicable).

Most cases with metastasis to the abdominal wall are described after percutaneous interventions including fine needle aspiration biopsy (FNAB), cytology, radiofrequency ablation or percutaneous ethanol injection (PEI). In the current literature during the last 10 years, only few cases have been reported with abdominal wall metastasis without prior seeding as a consequence of local interventions (see Tables 1 and 2).
Table 2

Study with 21 patients with 24 non-iatrogenic subcutaneous HCC metastases from 1 January 1998 to 31 December 2005[53]

 

Head

Chest

Back

Abdominal wall

Arms and legs

Huang Y-J et al. (2008) [53]

8

6

4

5

1

Long-term study on non-iatrogenic subcutaneous HCC metastases.

We present a case of a 75-year-old man with singular abdominal wall metastasis of differentiated, AFP-negative hepatocellular carcinoma without a history of prior seeding and without prior surgery to the abdominal wall. This is the first report of a case with hepatocellular carcinoma metastasis to the abdominal wall within a pre-existing subcutaneous lipoma since childhood and after antiandrogen therapy for prostate cancer since 2005.

This article provides a surgical approach, including abdominal wall reconstruction, and a current review of the literature as cited in PubMed.

Case presentation

Preoperative diagnostics and medical history

Our patient was referred to our center in March 2010 for diagnostic evaluation of a growing liver mass in liver segment II (3.9 × 2.6 × 3.0 cm). He was in good general condition with an obese nutritional status (Body Mass Index 30.4 kg/m²) and an impression of fatty liver parenchyma in ultrasound and magnetic resonance imaging. He was reported to drink two glasses of whisky per day. The previous history included multiple subcutaneous lipomas within the abdominal wall since childhood and prostate carcinoma, which was diagnosed in 2005 and removed by prostatectomy (pT2, pN0, MO, G3) in the same year, followed by antiandrogen therapy with leuprorelin and buserelin acetate until August 2008. The multiple lipomas showed a marked progression in size under antiandrogen therapy from August 2007 until August 2008. Final diagnostic evaluation, including ultrasound-guided FNAB of the liver mass and magnetic resonance imaging, resulted in the diagnosis of a multilocular, well-differentiated and AFP-negative hepatocellular carcinoma in liver segments II/III, VI, and VIII in April 2010. AFP levels stayed within normal range at all times during further follow-up. Viral hepatitis or other risk factors for hepatocellular carcinoma like hemochromatosis, liver fibrosis or liver cirrhosis could be ruled out. After interdisciplinary tumor board consultation (including surgeons, oncologists, radiologists, radio-oncologists and hepatologists) transarterial chemoembolisation (TACE) was performed from July 2010 to January 2011 every two months leading to a complete remission.

Consultation with our surgical service was initiated in November 2011 due to a hard palpable subcutaneous mass with a diameter of approximately 7 cm that had developed recently in the left upper abdominal wall, exactly where a soft subcutaneous lipoma manifestation has been, in the consciousness of the patient, since his childhood (see Figures 1 and 2). The patient assured us that FNAB had not been performed in the region of the pre-existing multiple lipomas in the left upper abdominal wall. This was consistent with the documentation of previous diagnostic work-up. Our patient was concerned about the marked change in size and consistency of the tumor in the left abdominal wall with concomitant darkening of the skin directly adjacent to the tumor (see Figure 2). Due to the patient’s medical history, the newly occurred subcutaneous tumorous mass in the left abdominal wall had to be suspected to be malignant. After ultrasound evaluation of the subcutaneous mass, a restaging computed tomography was initiated that demonstrated a tumor with a diameter of 7 cm within the left upper abdominal wall with no signs of lymph node metastasis, lung metastasis or any current hepatic tumor (see Figure 1). After interdisciplinary tumor board consultation (including surgeons, oncologists, radiologists, radio-oncologists and hepatologists) it was decided to recommend tumor resection and abdominal wall reconstruction.
Figure 1

Computed tomography scan showing a tumor with a diameter of 7 cm in the left upper abdominal wall.

Figure 2

Preoperative marking lines for the flap plastic.

Surgical therapy

We removed the tumor by resection of the skin with surrounding subcutaneous tissue en bloc with the surrounding upper left rectus abdominis muscle including the fascia. The resulting abdominal wall defect was too large for primary closure or component separation. We therefore decided to reconstruct the large defect in the abdominal wall fascia with a synthetic, partially resorbable monocryl-prolene mesh that we inserted into the defect of the fascia with a running monocryl-prolene suture without opening the peritoneal cavity. Fortunately, the peritoneum with the subfascial fat tissue layer could be easily separated from the tumor without risking incomplete resection. It was macroscopically evident that the peritoneum was not infiltrated by the tumor. In order to enable a tension-free primary wound and skin closure, we covered the mesh with a local flap and installed two Redon drains (size 12 Charrière) subcutaneously with suction for a total of five days (see Figures 2, 3 and 4).
Figure 3

Shown is the resected abdominal wall metastasis. The resection margins were macroscopically and microsopically tumor-free.

Figure 4

Abdominal wall six days after tumor resection with subcutaneous flap plastic and staple sutures.

Postoperative clinical course and histopathology

The clinical course after resection was uneventful. There was primary wound healing without any signs of infection or hematoma. Thus, the inserted drains could be removed after five days. Laboratory analysis evidenced slightly elevated infectious parameters during the first postoperative days, probably due to the surgical stimulus; however, these declined and were within normal range after hospital discharge. The mobilization was uneventful as well as oral food intake and intestinal motility.

Final pathological workup showed a hepatocellular carcinoma with a trabecular and pseudoglandular growth pattern (see Figure 5) with moderately atypical hepatocytes (G2) and multifocal bile formation without steatosis (see Figure 6). Immunohistochemistry was performed according to standard procedures using monoclonal antibodies for human androgen receptor (mouse clone AR441, Dako, Hamburg, Germany) as well as estrogen and progesterone receptor (rabbit SP1, and mouse PgR636, respectively, Dako) and polyclonal for AFP (rabbit, Dako). Multiple tissue blocks from different sites of the HCC showed no expression of the androgen receptor (see Figure 7). Furthermore, there was no detectable expression of AFP, estrogen or progesterone receptor. By gross examination, a subcutaneous lipomatous nodule of about 3 × 2 × 1.5 cm adjacent to the HCC could be identified. The histological findings were well compatible with the diagnosis of a lipoma, the sex hormone receptor status of the adipocytes was negative (Figures 8, 9).
Figure 5

Hepatocellular carcinoma with trabecular and pseudoglandular growth pattern (H&E stain, original magnification 20x).

Figure 6

Hepatocellular carcinoma with moderately atypical hepatocytes with multifocal bile formation (H&E stain, original magnification 200x).

Figure 7

Immunohistochemical staining for androgen receptor negative in the tumor cell nuclei (original magnification 200x).

Figure 8

Immunohistochemical staining for estrogen receptor: negative in the HCC (left) and lipomatous tissue (right) (original magnification 40x).

Figure 9

Detail from the lipoma: mature adipocytes with no atypia and a delicate fibrous tumor capsule (right, H&E stain) (original magnification 100x).

Discussion

Abdominal wall metastasis of primary hepatocellular carcinoma is generally a comparatively rare entity (for a summary of previously published cases, see Tables 1 and 2). Mostly described as the consequence of tumor seeding after percutaneous interventions, the metastatic potential of hepatocellular carcinoma without prior seeding has so far not been described in detail. The pathophysiological process of abdominal wall metastasis without prior seeding is poorly understood. In cases with liver cirrhosis, portal venous backflow mechanisms via collaterals in the abdominal wall may play a hypothetic role for the development of abdominal wall metastasis. Our patient had no cirrhosis and no significant portal venous collaterals in the abdominal wall.

Our patient underwent a previous prolonged period of antiandrogen therapy with leuprorelin and buserelin acetate with the intention to treat his prostate carcinoma until August 2008. It well may be that this treatment significantly contributed to the fact that our patient developed a differentiated, AFP-negative abdominal wall metastasis instead of undifferentiated HCC. Of note in this context is the histomorphologically mature phenotype of the HCC metastasis, the neoplastic hepatocytes showing no steatosis and no expression of the androgen receptor.

It is interesting to note that the abdominal wall lipoma demonstrated an accelerated growth during antiandrogen therapy. This may have contributed to haematogenous spread of HCC to the abdominal wall. Interestingly, numerous lines of evidence point to a role of androgens in the development of hepatocellular carcinoma [3742].

It could be demonstrated that the majority of hepatocellular carcinoma cells express androgen receptors in higher levels as compared to normal hepatocytes [3742]. Taken together epidemiologic, clinical, biologic and experimental studies have provided a strong rationale for antiandrogen therapy in hepatocellular carcinoma (HCC). Epidemiological studies demonstrated that the sex ratio for HCC arising in cirrhotic patients is eleven men for one woman, whereas the sex ratio in cirrhotic patients without HCC is less than two men for one woman [43]. Animal studies demonstrated that carcinogens induce HCC more easily in males than females. Matsumoto et al. could demonstrate that transforming growth factor alpha (TGF-alpha)-related hepatocarcinogenesis and hepatocyte proliferation are increased by androgenic stimulation in TGF-alpha transgenic mice [44]. Several clinical studies have reported occurrence of HCC after administration of androgen therapy (for example, with testosterone) in male subjects who suffer from aplastic anemia or infertility [4547]. Interestingly, stopping androgen therapy usually led to regression of the tumor [38].

Androgen receptors have been demonstrated in HCC in 74 % of males and 37 % of females, and their presence is associated with a more rapid progression of disease [40]. Arguments against our speculation that previous antiandrogen therapy may have caused the abdominal wall metastasis in our patient to be differentiated and AFP-negative may be derived from more recent data and the fact that immunhistochemical staining was negative in the tumor cell nuclei of our patient (see Figure 7). Antiandrogens (for example. leuprorelin) have been used in prospective randomized multicenter trials to treat hepatocellular carcinoma [38, 39]. One study with leuprorelin and flutamide demonstrated no benefit in survival for male patients with HCC treated with antiandrogens [39]. Another study showed a lack of efficacy of androgen treatment in unresectable HCC [38].

More recent studies with Cre-Lox conditional knockout mice model who lack androgen receptor (AR) expression demonstrated that the androgen receptor, but not androgens, may be a potential new and better therapeutic target for the treatment of HCC [48]. A new animal study found that hepatic androgen receptor promotes hepatitis B virus (HBV)-induced hepatocarcinogenesis in HBV transgenic mice that lack AR only in the liver hepatocytes (HBV-L-AR(−/y). HBV-L-AR(−/y) mice that received a low dose of the carcinogen N'-N'-diethylnitrosamine have a lower incidence of HCC and present with smaller tumor sizes, fewer foci formations, and less alpha-fetoprotein HCC marker than do their wild-type HBV-AR(+/y) littermates [49]. Taken together it appears that the androgen receptor in HCC may be more relevant for the biology of the tumor than the androgens or antiandrogen treatment.

Due to the low incidence of subcutaneous abdominal wall metastasis of HCC, therapeutic algorithms are widely missing. In the current literature, surgical resection is the favored therapeutic option [13, 23, 32]. However, surgical resection might be challenging depending on tumor size, invasiveness and localization. Immediate definitive closure of the wound is the preferred method. In cases with distinct wound distension, local inflammation or wound infect, temporary abdominal wall closure should be considered [50]. Meanwhile, abdominal wall reconstruction is necessary due to the resulting abdominal wall defect. Described methods include prosthetics or autologous reconstruction such as abdominal components separation or local flaps. Generally, deeper and larger wound defects that include the myofascia may require a synthetic, partially resorbable monocryl-prolene mesh to replace the resected myofascia that may have to be covered by a free tissue or a distant flap in order to reduce wound tension [51]. The local flap used in this case to cover the implanted partially resorbable monocryl-prolene mesh for abdominal wall reconstruction is a well-established procedure and proved successful during follow-up in this case [52]. In our opinion, resection of hepatocellular carcinoma metastases to the abdominal wall with peritoneal infiltration may require a modified approach for abdominal wall reconstruction, for example, with the use of a dual-layer mesh that is able to reduce postoperative adhesions between the intestine and the mesh within the intraperitoneal cavity. Fortunately in this case, opening of the peritoneal cavity could be avoided.

Huan et al. reported 21 patients with a subcutaneous HCC metastasis without seeding who were treated by radiotherapy (see Table 2) [53].

Single cases are not discussed in detail, so comparison with our work or the reports of other cases is barely possible. There is a substantial lack of evidence for adjuvant chemotherapeutic approaches after potentially curative resection of abdominal wall metastasis. In order to establish therapeutic algorithms for cutaneous metastasis of hepatocellular carcinoma, the initiation of large multicenter studies would be desirable in order to be able to create scientific evidence [54, 55]. Due to the rarity of cutaneous metastasis of hepatocellular carcinoma, this is a major and potentially unsolvable challenge.

Conclusions

We believe that in our case the abdominal wall metastasis is a consequence of systemic arterial tumor spread to a pre-existing lipoma since childhood via its blood supply. To our knowledge, this is the first report of such a case. Our case highlights that suspicion of abdominal wall metastasis of hepatocellular carcinoma is also justified in patients with pre-existing, long-standing palpable abdominal lipoma since childhood, especially when apparent growth of these nodules is being observed. We recommend surgical removal and abdominal wall reconstruction in such cases in palliative intention to avoid tumor necrosis at the abdominal wall and/or infiltration of the small or large bowel followed by potential percutaneous bowel perforation. Cases with a singular hepatocellular metastasis to the abdominal wall with otherwise complete surgical resection of the primary tumor may benefit from resection with potential improvement of survival.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Authors’ information

All authors of this article are clinically highly experienced physicians who are regularly involved with interdisciplinary treatment decisions for patients with hepatocellular carcinoma (HCC), encompassing up-to-date interventional, chemotherapeutic, and surgical approaches, including liver resection and liver transplantation, in one of the largest academic treatment centres for HCC in Germany.

Abbreviations

AFP: 

alpha-feto protein

AR: 

androgen receptor

FNAB: 

fine needle aspiration biopsy

H&E: 

hematoxylin and eosin

HBV: 

hepatitis B virus

HCC: 

hepatocellular carcinoma

n.a: 

not applicable

PEI: 

percutaneous ethanol injection

TACE: 

transarterial chemoembolisation

TGF-alpha: 

transforming growth factor alpha.

Declarations

Acknowledgements

The authors would like to acknowledge DFG sponsorship for the publication costs of open access publication.

Authors’ Affiliations

(1)
General, Visceral und Transplantation Surgery, Hanover Medical School
(2)
Trauma Department, Hanover Medical School
(3)
Institute of Pathology, Hanover Medical School
(4)
Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School

References

  1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecularcarcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.View ArticlePubMedGoogle Scholar
  2. Deuffic S, Poynard T, Buffat L, Valleron AJ: Trends in primary liver cancer. Lancet. 1998, 351: 214-215.View ArticlePubMedGoogle Scholar
  3. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, Galante D, Manghisi OG, Mazzanti R, Medaglia C, Pilleri G, Rapaccini GL, Simonetti RG, Taliani G, Tosti ME, Villa E, Gasbarrini G: Characteristics of hepatocellular carcinoma in Italy. J Hepatol. 1998, 29: 944-952. 10.1016/S0168-8278(98)80122-0.View ArticlePubMedGoogle Scholar
  4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase in primary liver cancer in the UK, 1979–94. Lancet. 1997, 350: 1142-1143.View ArticlePubMedGoogle Scholar
  5. Bosch FX, Ribes J, Díaz M, Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004, 127 (5 Suppl 1): S5-S16.View ArticlePubMedGoogle Scholar
  6. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005, 20: 1781-1787. 10.1111/j.1440-1746.2005.03919.x.View ArticlePubMedGoogle Scholar
  7. Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL: Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000, 216: 698-703.View ArticlePubMedGoogle Scholar
  8. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T: Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer. 1983, 51: 863-877. 10.1002/1097-0142(19830301)51:5<863::AID-CNCR2820510520>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
  9. Okuda K, Konda Y: Primary carcinoma of the liver. Bockus gastroenterology. Edited by: Haubrich WS, Schaffner F, Berk JE. 1995, WB Saunders, Philadelphia, 2444-2489. 5Google Scholar
  10. MacDonald RA: Primary carcinoma of the liver: a clinicopathological study of 108 cases. Arch Intern Med. 1967, 99: 266-79.View ArticleGoogle Scholar
  11. Jegou J, Perruzi P, Arav E, Pluot M, Jaussaud R, Remy G: Cutaneous and bone metastases revealing hepatocarcinoma. Gastroenterol Clin Biol. 2004, 28: 804-806. 10.1016/S0399-8320(04)95132-9.View ArticlePubMedGoogle Scholar
  12. de Agustín P, Conde E, Alberti N, Pérez-Barrios A, López-Ríos F: Cutaneous metastasis of occult hepatocellular carcinoma: a case report. Acta Cytol. 2007, 51: 214-216. 10.1159/000325720.View ArticlePubMedGoogle Scholar
  13. Hsieh CT, Sun JM, Tsai WC, Tsai TH, Chiang YH, Liu MY: Skull metastasis from hepatocellular carcinoma. Acta Neurochir (Wien). 2007, 149: 185-190. 10.1007/s00701-006-1071-3.View ArticleGoogle Scholar
  14. Royer MC, Rush WL, Lupton GP: Hepatocellular carcinoma presenting as a precocious cutaneous metastasis. Am J Dermatopathol. 2008, 30: 77-80. 10.1097/DAD.0b013e31815ea24f.View ArticlePubMedGoogle Scholar
  15. Magana M, Gomez LM: Skin metastasis from hepatocarcinoma. Am J Dermatopathol. 2009, 31: 502-505. 10.1097/DAD.0b013e31819d095e.View ArticlePubMedGoogle Scholar
  16. Lazaro M, Allende I, Ratón JA, Acebo E, Diaz-Perez JL: Cutaneous metastases of hepatocellular carcinoma. Clin Exp Dermatol. 2009, 34: e567-569. 10.1111/j.1365-2230.2009.03245.x.View ArticlePubMedGoogle Scholar
  17. Fukushima M, Katagiri A, Mori T, Watanabe T, Katayama Y: Case of skull metastasis from hepatocellular carcinoma at the site of skull fracture. No Shinkei Geka. 2010, 38: 371-377.PubMedGoogle Scholar
  18. Lee GK, Lorenz HP, Mohan SV: A rare case of mistaken identity: metastatic hepatocellular carcinoma to the nose. JSCR. 2010, 4: 3-Google Scholar
  19. Isa NM, Bong JJ, Ghani FA, Rose IM, Husain S, Azrif M: “Cutaneous metastasis of hepatocellular carcinoma diagnosed by fine needle aspiration cytology and Hep Par 1 immunopositivity“. Diagn Cytopathology. 2011, 10.1002/dc.21706.Google Scholar
  20. Ackerman D, Barr RJ, Elias AN: Cutaneous metastases from hepatocellular carcinoma. Int J Dermatol. 2001, 40: 782-784. 10.1046/j.1365-4362.2001.01319.x.View ArticlePubMedGoogle Scholar
  21. Braune C, Widjaja A, Bartels M, Bleck JS, Flemming P, Manns MP, Klempnauer J, Gebel M: Surgical removal of a distinct subcutaneous metastasis of multilocular hepatocellular carcinoma 2 months after initial percutaneous ethanol injection therapy. Z Gastroenterol. 2001, 39: 789-792. 10.1055/s-2001-17188.View ArticlePubMedGoogle Scholar
  22. Al-Mashat FM: Hepatocellular carcinoma with cutaneous metastasis. Saudi Med J. 2004, 25: 370-372.PubMedGoogle Scholar
  23. Amador A, Monforte NG, Bejarano N, Martí J, Artigau E, Navarro S, Fuster J: Cutaneous metastasis from hepatocellular carcinoma as the first clinical sign. J Hepatobiliary Pancreat Surg. 2007, 14: 328-330. 10.1007/s00534-006-1141-1.View ArticlePubMedGoogle Scholar
  24. Terada T, Sugiura M: “Metastatic hepatocellular carcinoma of skin diagnosed with hepatocyte paraffin 1 and a-fetoprotein immunostainings“. Int J Surg Pathol. 2010, 18: 433-436.PubMedGoogle Scholar
  25. Suzuki H, Kuwano H, Masuda N, Hashimoto S, Saitoh T, Kanoh K, Nomoto K, Shimura T: Resected case of a double cancer, a hepatocellular carcinoma and cholangiocellular carcinoma, and their spread to the skin. Hepatogastroenterology. 2003, 50: 362-365.PubMedGoogle Scholar
  26. Lee MC, Huang YL, Yang CH, Kuo TT, Hong HS: Cutaneous seeding of hepatocellular carcinoma due to percutaneous ethanol injection and masquerading as a pyogenic granuloma. Dermatol Surg. 2004, 30: 438-10.1111/j.1524-4725.2004.30120.x.PubMedGoogle Scholar
  27. Hyun YS, Choi HS, Bae JH, Jun DW, Lee HL, Lee OY, Yoon BC, Lee MH, Lee DH, Kee CS, Kang JH, Park MH: Chest wall metastasis from unknown primary site of hepatocellular carcinoma. World J Gastroenterol. 2006, 12: 2139-2142.PubMed CentralPubMedGoogle Scholar
  28. Nggada HA, Ajayi NA: “Cutaneous metastasis from hepatocellular carcinoma: a rare presentation and review of the literature“. Afr J Med Med Sci. 2006, 35 (2): 181-182. reviewPubMedGoogle Scholar
  29. Martínez Ramos D, Villegas Cánovas C, Senent Vizcaíno V: “Subcutaneous seeding of hepatocellular carcinoma after fine-needle percutaneous biopsy“. Rev Esp Enferm Dig. 2007, 99 (6): 354-357. SpanishView ArticlePubMedGoogle Scholar
  30. Rowe LR, Mulvihill SJ, Emerson L, Gopez EV: Subcutaneous tumor seeding following needle core biopsy of hepatocellular carcinoma. Diagn Cytopathol. 2007, 35: 717-721. 10.1002/dc.20717.View ArticlePubMedGoogle Scholar
  31. Özdil B, Akkiz H, Sandikci M: Giant subcutaneous HCC case occurring after percutaneous ethanol injection. Turk J Gastroenterol. 2009, 20: 301-302.PubMedGoogle Scholar
  32. Chen YY, Yen HH: Subcutaneous metastases after laparoscopic-assisted partial hepatectomy for hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2011, 21: e41-43. 10.1097/SLE.0b013e3182078ac3.View ArticlePubMedGoogle Scholar
  33. Fang YR, Huang YS, Wu JC, Chao Y, Tsay SH, Chan CY, Chang FY, Lee SD: An unusual cutaneous metastasis from hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 2001, 64: 253-257.PubMedGoogle Scholar
  34. Kanitakis J, Causeret AS, Claudy A, Scoazec JY: Cutaneous metastasis of hepatocellular carcinoma diagnosed with hepatocyte paraffin (Hep Par 1) antibody immunohistochemistry. J Cutan Pathol. 2003, 30: 637-640. 10.1034/j.1600-0560.2003.00128.x.View ArticlePubMedGoogle Scholar
  35. Nagaoka Y, Nakayama R, Iwata M: Cutaneous seeding following percutaneous ethanol injection therapy for hepatocellular carcinoma. Intern Med. 2004, 43: 268-269. 10.2169/internalmedicine.43.268.View ArticlePubMedGoogle Scholar
  36. Masannat YA, Achuthan R, Munot K, Merchant W, Meaney J, McMahon MJ, Horgan KJ: Solitary subcutaneous metastatic deposit from hepatocellular carcinoma. N Z Med J. 2007, 120: U2837-PubMedGoogle Scholar
  37. Zhang J, Huang G, Huang W: Gonadotropin releasing hormone and its receptor in the tissue of human hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 1998, 78: 343-346.PubMedGoogle Scholar
  38. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J: Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998, 16: 411-417.PubMedGoogle Scholar
  39. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire: Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology. 2004, 40: 1361-1369.View ArticleGoogle Scholar
  40. Nagasue N, Chang YC, Hayashi T, Galizia G, Kohno H, Nakamura T, Yukaya H: Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg. 1989, 209: 424-427. 10.1097/00000658-198904000-00006.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Nagasue N, Galizia G, Yukaya H, Kohno H, Chang YC, Hayashi T, Nakamura T: Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology. 1989, 36: 379-383.PubMedGoogle Scholar
  42. Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G: Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. Liver. 1994, 14: 213-219. 10.1055/s-2007-1007312.View ArticlePubMedGoogle Scholar
  43. Johnson PJ, Krasner N, Portmann B, Eddleston AL, Williams R: Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut. 1978, 19: 1022-1026. 10.1136/gut.19.11.1022.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Matsumoto T, Takagi H, Mori M: Androgen dependency of hepatocarcinogenesis in TGFalpha transgenic mice. Liver. 2000, 20: 228-33. 10.1034/j.1600-0676.2000.020003228.x. A published erratum appears in Liver 2004, 24:275View ArticlePubMedGoogle Scholar
  45. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H: Androgen-induced hepatoma. Lancet. 1975, 1: 430-432.View ArticlePubMedGoogle Scholar
  46. Guy JT, Auslander MO: Androgenic steroids and hepatocellular carcinoma. Lancet. 1973, 1: 148-View ArticlePubMedGoogle Scholar
  47. Goldfarb S: Sex hormones and hepatic neoplasia. Cancer Res. 1976, 36: 2584-2588.PubMedGoogle Scholar
  48. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C: Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008, 135: 947-955. 10.1053/j.gastro.2008.05.046.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C: Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010, 2: 32ra35-10.1126/scitranslmed.3001143.PubMed CentralPubMedGoogle Scholar
  50. Rohrich RJ, Lowe JB, Hackney FL, Bowman JL, Hobar PC: Plast Reconstr Surg. An algorithm for abdominal wall reconstruction. Plast Reconstr Surg. 2000, 105: 202-216. 10.1097/00006534-200001000-00036.View ArticlePubMedGoogle Scholar
  51. Rudolph R, Klein L: Healing process in skin grafts. Surg Gynecol Obstet. 1973, 136: 641-654.PubMedGoogle Scholar
  52. Buck DW, Khalifeh M, Redett RJ: Plastic surgery repair of abdominal wall and pelvic floor defects. Urol Oncol. 2007, 25: 160-164. 10.1016/j.urolonc.2006.09.009.View ArticlePubMedGoogle Scholar
  53. Huang YJ, Tung WC, Hsu HC, Wang CY, Huang EY, Fang FM: Radiation therapy to non-iatrogenic subcutaneous metastasis in hepatocellular carcinoma: results of a case series. Br J Radiol. 2008, 81: 143-150. 10.1259/bjr/81811976.View ArticlePubMedGoogle Scholar
  54. Levels of Evidence. Oxford Centre for Evidence-based Medicine. 2009,http://www.cebm.net/index.aspx?o=1025.2010,
  55. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011, 253: 453-469. 10.1097/SLA.0b013e31820d944f.View ArticlePubMedGoogle Scholar

Copyright

© Zachau et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.